chevron-down Created with Sketch Beta.
January 27, 2023

Analysts Predict Important Year for Cancer Cell-Based Therapies

Endpoints News reports that as a number of drug candidates make their way through clinical trials, many analysts believe 2023 will be an “important” year for the ongoing development of both allogeneic and autologous cell-based therapies for the treatment of multiple myeloma and non-Hodgkin's lymphoma. 

The material in all ABA publications is copyrighted and may be reprinted by permission only. Request reprint permission here.